<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01063569</url>
  </required_header>
  <id_info>
    <org_study_id>3.2007.2343</org_study_id>
    <secondary_id>2009-010917-61</secondary_id>
    <nct_id>NCT01063569</nct_id>
  </id_info>
  <brief_title>Glucocorticoid Treatment in Addison's Disease</brief_title>
  <official_title>Glucocorticoid Treatment in Addison's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Addison's disease is a rare condition which in most cases is caused by autoimmune destruction
      of the adrenals, leading to deficiency of cortisol, aldosterone and adrenal androgens.
      Unrecognized the disease is life threatening, but with proper treatment patients can live
      near normal lives.

      The conventional glucocorticoid replacement therapy renders the cortisol levels
      unphysiological, which may cause symptoms and long-term complications. Glucocorticoid
      replacement therapy is technically feasible by continuous subcutaneous hydrocortisone
      infusion (CSHI), and can mimic the normal diurnal cortisol rhythm. This study aims to further
      evaluate CSHI treatment in terms of metabolic effects, effects on health-related
      quality-of-life and sleep in an 8 months randomised open label clinical trial with crossover
      design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morning (08-09) plasma ACTH</measure>
    <time_frame>Time 0, months 2, 3, 5, 7 and 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life; evaluated by SF-36 vitality scores and AddiQoL scores</measure>
    <time_frame>At time 0 and months 2,3,5,7 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep; evaluated by Pittsburgh Sleep Quality Index (PSQI), and 7-days' Actigraph registration combined with self-reported sleep diary</measure>
    <time_frame>PSQI: 0 and months 2,3,5,7 and 8; Actigraph/sleep diary: months 2 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h cortisol profiles in serum and saliva</measure>
    <time_frame>months 2 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-glucose, 24 h profile</measure>
    <time_frame>months 2 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity assessed by euglycemic clamp</measure>
    <time_frame>Months 2 and 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Addison's Disease</condition>
  <arm_group>
    <arm_group_label>Oral hydrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Continous subcutaneous hydrocortisone infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solu-Cortef (hydrocortisone)</intervention_name>
    <description>Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.</description>
    <arm_group_label>Continous subcutaneous hydrocortisone infusion</arm_group_label>
    <other_name>Solu-Cortef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cortef (hydrocortisone)</intervention_name>
    <description>Oral treatment 3 times a day. Weight adjusted doses.</description>
    <arm_group_label>Oral hydrocortisone</arm_group_label>
    <other_name>Cortef 5 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with verified Addison's disease on stable treatment.

        Exclusion Criteria:

          -  Insulin treated Diabetes Mellitus, cardiovascular disease,malignant disease,
             pregnancy.

          -  Treatment with glucocorticoids or drugs that interfere with cortisol metabolism
             (antiepileptics, rifampicin, St. John's wart).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristian Løvås, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2010</study_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Addison's disease</keyword>
  <keyword>Glucocorticoid treatment</keyword>
  <keyword>Continuous subcutaneous hydrocortisone infusion</keyword>
  <keyword>CSHI</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Sleep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Addison Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

